A Retrospective Study Comparing the Severe Cutaneous Adverse Reactions in Patients Receiving Triazole Antifungal Therapy and Literature Analysis

Clicks: 3
ID: 325159
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #131 of 159 articles by views in medical mycology

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 159 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Triazole antifungal drugs (TADs) are widely used in clinical practice but carry a risk of severe cutaneous adverse reactions (SCARs). However, comprehensive real-world evidence regarding the comparative safety profiles of individual TADs remains limited. This research aimed to investigate and compare the real-world risk, clinical characteristics, and time-to-onset of SCARs associated with individual TADs. The SCAR cases with TADs as the primary suspect drug were identified in the FDA Adverse Event Reporting System. Disproportionality analysis and Bayesian methods were employed to detect safety signals with Reporting Odds Ratio (ROR), Proportional Reporting Ratio (PRR), Bayesian Confidence Propagation Neural Network (BCPNN), and Empirical Bayes Geometric Mean (EBGM). Differences of clinical features, outcomes, time-to-onset (TTO), and signal strength at the preferred term (PT) level were analyzed. A total of 1 429 SCAR cases with five TADs were identified. Fluconazole showed the strongest and most consistent statistical association across all four algorithms (ROR = 5.2), followed by itraconazole. Voriconazole yielded mixed signals (positive by ROR and BCPNN only), while Posaconazole and Isavuconazole exhibited no significant SCAR signals. Voriconazole was associated with the highest mortality proportion (12.8%), followed by posaconazole (10%). The median TTO for SCARs was 8 days, with voriconazole having the longest delay (16 days). At the PT level, 45 distinct signals were identified, including high-risk manifestations such as fixed eruption (ROR = 24.43), mucosal ulceration, and SJS/TEN overlap. This study identified significant variability of SCARs signals among triazole antifungals. These findings support early risk recognition and informed antifungal selection in clinical practice.
Reference Key
openalex_W7203636424 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Chengtao Jin, Qian-Qian Jiang, Ping Chen, Wei Jiang
Journal medical mycology
Year 2026
DOI
10.1093/mmy/myag084
URL
https://doi.org/10.1093/mmy/myag084
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.